^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Malignant Pleural Mesothelioma |
| Drug: | carboplatin (Tubulin polymerization promoter) + pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published date:
07/28/2015
Excerpt:
Recommendation 4...The first- and second-line treatment of unresectable mesothelioma...Anti-folate/platinum doublet is the only approved standard of care...Combination doublet chemotherapy of cisplatin, with either pemetrexed or raltitrexed, has shown a longer survival compared with cisplatin alone…Carboplatin is an acceptable alternative to cisplatin and may be better tolerated in the elderly population.
DOI:
doi:10.1093/annonc/mdv199
Source:
Excerpt:
Other acceptable first-line combination chemotherapy options recommended by NCCN include: 1) pemetrexed/carboplatin, which was assessed in 3 large phase 2 studies...or 2) gemcitabine/cisplatin, which was also assessed in Phase 2 studies...
Source:
Title:
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
Excerpt:
The pemetrexed plus cisplatin group demonstrated a response rate of 26.3% compared with 21.7% for the pemetrexed plus carboplatin group, with similar 1-year survival rates (63.1% versus 64.0%) and median time to progressive disease (7 months versus 6.9 months)....This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaïve patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.
DOI:
10.1097/JTO.0b013e31817c73d6
